Back to User profile » Dr Jason Bacharach

Papers published by Dr Jason Bacharach:

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial

Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C

Clinical Ophthalmology 2023, 17:2575-2588

Published Date: 1 September 2023

Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial

Schechter BA, Urbieta M, Bacharach J, Toyos M, Smyth-Medina R, Mitchell B, Luchs JI

Clinical Ophthalmology 2022, 16:4145-4151

Published Date: 13 December 2022

First Real-World, Multicenter, Post-Marketing, Retrospective Study of Dexamethasone Intraocular Suspension for Inflammation After Cataract Surgery

Bacharach J, McCabe C, Jackson M, Rao S, Singh IP, Heersink S, Radcliffe N, Weinstock R, Paggiarino D, Patel K

Clinical Ophthalmology 2022, 16:1783-1794

Published Date: 3 June 2022

Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials

Wirta DL, Korenfeld MS, Foster S, Smyth-Medina R, Bacharach J, Kannarr SR, Jaros MJ, Slonim CB

Clinical Ophthalmology 2021, 15:4035-4048

Published Date: 8 October 2021

Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results

Bacharach J, Wirta DL, Smyth-Medina R, Korenfeld MS, Kannarr SR, Foster S, Jaros MJ, Slonim CB

Clinical Ophthalmology 2021, 15:2743-2751

Published Date: 25 June 2021

Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies

Shen Lee B, Kabat AG, Bacharach J, Karpecki P, Luchs J

Clinical Ophthalmology 2020, 14:119-126

Published Date: 14 January 2020